This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Treat vitamin D deficiency to prevent deadly ... Vitamin D supplements have been found to reduce the risk of ... (13 Jan 2019)
Even moderate alcohol consumption is a risk ... A new study published in HeartRhythm reports that regular ... (13 Jan 2019)
Are Your Facebook Friends Making You Feel ... Research published in Heliyon finds that Facebook users who ... (13 Jan 2019)
High intake of dietary fibre and whole ...   High intake of dietary fibre and whole grains associated ... (13 Jan 2019)
Newborns Face Risks When Born to Women with ... Pregnant women with influenza are more likely to experience ... (11 Jan 2019)
Wednesday, 14 November 2018 07:45

Study Explores Timing of Muscle-Related Problems of Statin Use Featured

Rate this item
(0 votes)

Statins have been linked with muscle pain and other musculoskeletal adverse events (MAEs) in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.


For the study, cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and pravastatin) were prescribed were extracted from the US Food and Drug Administration Adverse Event Reporting System Data Files.

The onset timing of statin-induced musculoskeletal adverse events (MAEs) differed with each statin. For example, the onset of MAEs was significantly faster with high-intensity statins including atorvastatin and rosuvastatin than with simvastatin. Concomitant use of drugs—even those that may increase the risk of MAEs—did not cause changes in the onset timing of MAEs associated with statins.

“Passive surveillance of adverse events has played a major role in securing drug safety as a system to detect unknown adverse events. Data mining using Food and Drug Administration Adverse Event Reporting System, which is a large-scale database, will be an aid to enhance drug safety,” said senior author Dr. Daiuke Kobayashi, of Josai University, in Japan.



Source: Wiley
Full bibliographic information

Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Pharmacol Res Perspect. 2018;e00439. 

Read 172 times

Latest news

Highlights

  • WASP - Writing A Scientific Paper

    Quantitative Statistical Analysis
    3-5th April 2019 @ Malta Life Sciences Park
    San Gwann, Malta
    Endorsed by EBCOG and MIPS

    The Write a Scientific Paper (WASP) is an intensive 3 day course that covers all aspects pertaining to writing a scientific paper: from proposal to data protection, data gathering, analysis, writing, dealing with editors and presenting one's research. WASP's uniqueness is its breadth, particularly the statistical analysis sections which are explained in an extremely simple manner.

    Written on December 21, 2018 Read more...
  • FULL TIME MEDICAL REPRESENTATIVE

    A new vacancy has arisen within the Healthcare Division of the Company for a Full Time Medical Representative. Click here for more information.

    Written on December 12, 2018 Read more...

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…